Q4 Earnings Forecast for AXSM Issued By William Blair

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities research analysts at William Blair issued their Q4 2025 earnings per share (EPS) estimates for Axsome Therapeutics in a research note issued on Monday, November 3rd. William Blair analyst M. Minter expects that the company will earn ($0.70) per share for the quarter. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. William Blair also issued estimates for Axsome Therapeutics’ Q1 2026 earnings at ($0.56) EPS, Q2 2026 earnings at $0.05 EPS, Q3 2026 earnings at $0.61 EPS and Q4 2026 earnings at $1.35 EPS.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.12). Axsome Therapeutics had a negative net margin of 49.88% and a negative return on equity of 283.22%. The firm had revenue of $170.99 million during the quarter, compared to analysts’ expectations of $162.96 million. The company’s revenue for the quarter was up 63.2% compared to the same quarter last year.

A number of other equities research analysts have also recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Axsome Therapeutics in a report on Wednesday, October 8th. Needham & Company LLC reissued a “buy” rating and set a $154.00 target price on shares of Axsome Therapeutics in a report on Tuesday. HC Wainwright boosted their target price on shares of Axsome Therapeutics from $180.00 to $185.00 and gave the company a “buy” rating in a report on Tuesday. Morgan Stanley boosted their target price on shares of Axsome Therapeutics from $194.00 to $196.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, Guggenheim boosted their target price on shares of Axsome Therapeutics from $200.00 to $205.00 and gave the company a “buy” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Axsome Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $180.75.

Axsome Therapeutics Price Performance

Axsome Therapeutics stock opened at $135.69 on Wednesday. Axsome Therapeutics has a 12 month low of $75.56 and a 12 month high of $139.13. The company has a current ratio of 1.57, a quick ratio of 1.51 and a debt-to-equity ratio of 1.66. The business’s 50 day simple moving average is $124.02 and its 200 day simple moving average is $113.19. The company has a market cap of $6.77 billion, a price-to-earnings ratio of -26.76 and a beta of 0.52.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Moors & Cabot Inc. increased its holdings in shares of Axsome Therapeutics by 4.5% in the second quarter. Moors & Cabot Inc. now owns 2,330 shares of the company’s stock worth $243,000 after purchasing an additional 100 shares during the period. Meridian Wealth Management LLC increased its stake in Axsome Therapeutics by 0.5% in the third quarter. Meridian Wealth Management LLC now owns 22,124 shares of the company’s stock valued at $2,687,000 after acquiring an additional 103 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Axsome Therapeutics by 1.1% in the second quarter. China Universal Asset Management Co. Ltd. now owns 9,889 shares of the company’s stock valued at $1,032,000 after acquiring an additional 107 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its stake in Axsome Therapeutics by 6.8% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 2,101 shares of the company’s stock valued at $255,000 after acquiring an additional 134 shares during the last quarter. Finally, Mutual of America Capital Management LLC increased its stake in Axsome Therapeutics by 0.3% in the first quarter. Mutual of America Capital Management LLC now owns 39,623 shares of the company’s stock valued at $4,621,000 after acquiring an additional 136 shares during the last quarter. Institutional investors own 81.49% of the company’s stock.

Insider Transactions at Axsome Therapeutics

In other news, CEO Herriot Tabuteau sold 91,705 shares of the company’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $132.34, for a total value of $12,136,239.70. Following the transaction, the chief executive officer owned 7,229 shares of the company’s stock, valued at approximately $956,685.86. This represents a 92.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Roger Jeffs sold 20,000 shares of the company’s stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $121.60, for a total transaction of $2,432,000.00. Following the completion of the transaction, the director directly owned 90,974 shares in the company, valued at approximately $11,062,438.40. The trade was a 18.02% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 407,271 shares of company stock valued at $50,640,415. 22.30% of the stock is currently owned by company insiders.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.